ADAPT

  • Development of an automated system for handling and deposition of tumoroids.
  • ADAPT is a joint project conducted in collaboration with engineers at the Hahn-Schickard Institute for Microanalysis Systems and the Department of Microsystems Engineering (IMTEK) at the University of Freiburg. The project is financed by a 1.000.000 EUR grant from the “Alternative Methods to Animal Testing” initiative of the German Federal Ministry of Education and Research. 2cureX will receive 110.500 EUR to validate the novel technology and integrate it into the IndiTreat® test.
  • The funds enable the development of a device for in vitro experiments with tumoroids from human tissue that meets the requirements for personalized medicine in terms of miniaturization, standardization, automation, flexibility and throughput.
  • Automation of tumoroid handling will increase the applicability of functional testing in clinical practice and improve the precision of the IndiTreat® test. This will ensure constant operator-independent quality standards across different hospitals where IndiTreat® is being implemented.
  • ADAPT started in April 2020 and will run for 36 month.

Project Details

Acronym:
ADAPT

Grant agreement ID:
031L0235C

Duration:
36 months

Start date:
1 April 2020

Topic:
Alternative Methods to Animal Testing

Funding:
110.500 EUR

Upcoming events

October 13, 2022

2cureX presents at Redeye Investor AW in Malmø, Sweden

Redeye events list

October 26, 2022

2cureX presents at Redeye Medtech event in Stockholm, Sweden

Redeye events list

November 24, 2022

Interim Report Q3 2022 released

View previous reports

November 24, 2022

Q3 Report webcast and Q&A session

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.